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Summary
Background Pakistan and Afghanistan are two of the three remaining countries yet to interrupt wild-type poliovirus 
transmission. The increasing incidence of poliomyelitis in these countries during 2010–11 led the Executive Board of 
WHO in January, 2012, to declare polio eradication a “programmatic emergency for global public health”. We aimed 
to establish why incidence is rising in these countries despite programme innovations including the introduction of 
new vaccines.
Methods We did a matched case-control analysis based on a database of 46 977 children aged 0–14 years with onset of 
acute ﬂ accid paralysis between Jan 1, 2001, and Dec 31, 2011. The vaccination history of children with poliomyelitis 
was compared with that of children with acute ﬂ accid paralysis due to other causes to estimate the clinical eﬀ ectiveness 
of oral poliovirus vaccines (OPVs) in Afghanistan and Pakistan by conditional logistic regression. We estimated 
vaccine coverage and serotype-speciﬁ c vaccine-induced population immunity in children aged 0–2 years and assessed 
their association with the incidence of poliomyelitis over time in seven regions of Afghanistan and Pakistan.
Findings Between Jan 1, 2001, and Dec 31, 2011, there were 883 cases of serotype 1 poliomyelitis (710 in Pakistan and 
173 in Afghanistan) and 272 cases of poliomyelitis serotype 3 (216 in Pakistan and 56 in Afghanistan). The estimated 
clinical eﬀ ectiveness of a dose of trivalent OPV against serotype 1 poliomyelitis was 12·5% (95% CI 5·6–18·8) 
compared with 34·5% (16·1–48·9) for monovalent OPV (p=0·007) and 23·4% (10·4–34·6) for bivalent OPV 
(p=0·067). Bivalent OPV was non-inferior compared with monovalent OPV (p=0·21). Vaccination coverage decreased 
during 2006–11 in the Federally Administered Tribal Areas (FATA), Balochistan, and Khyber Pakhtunkhwa in Pakistan 
and in southern Afghanistan. Although partially mitigated by the use of more eﬀ ective vaccines, these decreases in 
coverage resulted in lower vaccine-induced population immunity to poliovirus serotype 1 in FATA and Balochistan 
and associated increases in the incidence of poliomyelitis. 
Interpretation The eﬀ ectiveness of bivalent OPV is comparable with monovalent OPV and can therefore be used in 
eradicating serotype 1 poliomyelitis whilst minimising the risks of serotype 3 outbreaks. However, decreases in 
vaccination coverage in parts of Pakistan and southern Afghanistan have severely limited the eﬀ ect of this vaccine. 
Funding Poliovirus Research subcommittee of WHO, Royal Society, and Medical Research Council. 
Introduction 
The sustained eﬀ ort of the Global Polio Eradication 
Initiative (GPEI) to vaccinate children in Afghanistan and 
Pakistan reduced cases of serotype 1 and 3 polio myelitis 
between 2005 and 2007 in both countries.1 However, since 
2008, the annual incidence of polio myelitis in Afghanistan 
and Pakistan has increased, and in 2011, Pakistan reported 
the highest incidence of polio myelitis in a decade.2 Over 
60% of all cases in endemic countries and 34% of cases 
worldwide were recorded in Pakistan,2 which risks being 
the last country to interrupt transmission, and so is 
jeopardising global polio erad ication. In July, 2011, cases 
of poliomyelitis identiﬁ ed in children in the western 
region of China (Xinjiang autonomous region) were 
genetically linked to cases in Pakistan, showing the risk to 
other countries of poliomyelitis in Pakistan.3 
Since the turn of the century there have been several 
developments in the GPEI strategy. Until 2005, GPEI 
relied on the trivalent form of the oral poliovirus vaccine 
(OPV), which contains all three serotypes. Use of trivalent 
OPV results in reduced eﬀ ectiveness against individual 
serotypes, in particular serotypes 1 and 3, because of 
interference between Sabin vaccine strains.4 To address 
this problem, serotype 1 and 3 monovalent OPVs were 
produced and licensed in 2005 (wild-type poliovirus 
serotype 2 was eliminated in 1999). These vaccines are 
more immunogenic and more eﬀ ective than the trivalent 
vaccine.5–7 In late 2009 and early 2010, a serotype 1 and 3 
bivalent OPV was licensed and pre-qualiﬁ ed by WHO 
and introduced into Afghanistan and Pakistan after its 
immunogenicity was shown to be non-inferior compared 
with monovalent OPV for each serotype in a study among 
neonates in India.8 
Since the introduction of these improved vaccines to 
Pakistan and Afghanistan,9 one would have expected a 
reduction in cases. However, polio eradication in 
Pakistan has been aﬀ ected by weak service delivery10 and 
was identiﬁ ed by the GPEI Independent Monitoring 
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Board in 2010 as a country that was not on track for 
elimination of poliomyelitis.2,11 The eradication of polio-
myelitis in parts of Pakistan and Afghanistan has been 
complicated by armed conﬂ ict, security concerns 
(eg, areas being inaccessible to vaccination teams 
because of security concerns, and the movement of 
families to escape potential conﬂ ict), cultural barriers, 
and natural disasters that have limited accessibility of 
vaccination teams to target populations. Because of the 
deterioration of the programme in Pakistan and 
Afghanistan in 2011, and ongoing transmission of polio-
viruses in Nigeria, on Jan 21, 2012, the WHO Executive 
Board declared polio eradication a “program matic 
emergency for global public health”.12
Because poliovirus remains endemic in Pakistan and 
Afghanistan, identifying where the programme is 
failing to immunise children is imperative, so that 
appropriate improvements to the vaccination pro-
gramme can be made. Although independent monitor-
ing of immunisation campaigns can provide an esti mate 
of coverage,10 these data do not easily translate to 
estimates of serotype-speciﬁ c immunity. Further more, 
recent lot quality assurance sampling of vaccination 
coverage during campaigns suggested that independent 
monitoring might signiﬁ cantly over estimate coverage.13
Recording a child’s vaccination history during the 
investigation of acute ﬂ accid paralysis provides an 
opportunity to assess vaccination coverage and eﬀ ective-
ness in Pakistan and Afghanistan. We used vaccination 
history data from children with acute ﬂ accid paralysis to 
estimate the clinical eﬀ ectiveness and population 
immunity induced by OPVs. We assessed programme 
performance over time in diﬀ erent regions and examined 
the association between estimated serotype-speciﬁ c 
population immunity and the incidence of poliomyelitis. 
The results are discussed to highlight improvements that 
must be made to ensure elimination of poliomyelitis in 
these endemic countries. 
Methods 
Data collection 
Children are vaccinated using the OPV through either 
routine immunisation as part of the WHO Expanded 
Programme on Immunisation or via supplementary 
immunisation activities, where vaccination teams aim to 
vaccinate all children aged 0–4 years within a few days 
through ﬁ xed booths and mobile vaccination teams. 
Initial case investigation includes an interview with the 
child’s caregiver to record demographic information 
(age, date of birth, sex, district of residence, and details 
of illness) and vaccination history, including the 
num ber of OPV doses received through routine and 
supplementary immunisation activities. Two stool 
samples are collected at least 24 h apart within 14 days of 
the onset of paralysis and are sent under appropriate 
conditions to the WHO reference laboratory in 
Islamabad, Pakistan, where they are tested for the 
presence of wild-type and vaccine-related poliovirus.14 
We analysed data from 46 977 children in Pakistan and 
Afghanistan who had an onset of acute ﬂ accid paralysis 
between Jan 1, 2001, and Dec 31, 2011. Although acute 
ﬂ accid paralysis surveillance began in Pakistan in 1995 
and in Afghanistan in 1997, a virological case deﬁ nition 
based on isolation of wild-type poliovirus from stool 
samples was not adopted until January, 2000, in Pakistan 
and January, 2001, in Afghanistan.15,16 Further more, indi-
cators of surveillance performance in both countries 
before 2001, were poor and did not meet international 
standards (appendix).15 We therefore excluded children 
with acute ﬂ accid paralysis reported before January, 2001.
Children with acute ﬂ accid paralysis and wild-type 
poliovirus detected in at least one stool sample were 
deﬁ ned as poliomyelitis cases. Children with acute ﬂ accid 
paralysis and two adequate stool samples in which neither 
wild-type nor vaccine-related poliovirus were isolated were 
deﬁ ned as non-polio acute ﬂ accid paralysis. Children 
without suﬃ  cient information about age, date of birth, 
district of residence, or OPV vaccine history, and children 
without two adequately collected stool samples and with 
residual paralysis compatible with poliomyelitis 
(compatible cases), were excluded from the analysis 
(appendix). We also excluded children with vaccine-derived 
poliovirus isolated from their stool. Serotype 2 circulating 
vaccine-derived poliovirus was isolated from six children 
in Afghanistan between June, 2010, and January 2011; no 
other circulating vaccine-derived polio virus was reported 
from Afghanistan or Pakistan.17 
For each acute ﬂ accid paralysis case, the numbers of 
OPV doses received through routine and supplementary 
immunisation activities, as reported by the caregiver, 
were separately recorded. All OPV doses received 
through routine services were trivalent. Vaccinations 
See Online for appendix
Number of 
cases of 
poliomyelitis
Number of 
cases matched 
to a control (%)
Mean age (SD; months) Mean number of OPV 
doses (SD) 
Cases Controls Cases Controls
Pakistan
Balochistan 128 59 (46%) 19·0 (12·1) 18·5 (12·4) 2·8 (3·9) 3·9 (4·2)
FATA 140 67 (48%) 14·7 (8·9) 16·3 (8·8) 2·8 (4·8) 5·0 (5·8)
KP 140 77 (55%) 17·9 (9·2) 18·0 (9·2) 4·3 (5·6) 6·9 (5·4)
Punjab+ 124 83 (67%) 16·0 (12·5) 15·8 (12·4) 7·2 (5·2) 7·9 (6·0)
Sindh 178 117 (66%) 28·0 (26·2) 28·2 (26·3) 6·9 (4·5) 8·2 (4·6)
All areas 710 403 (57%) 20·1 (17·5) 20·3 (17·5) 5·2 (5·1) 6·7 (5·4)
Afghanistan
Southern 144 113 (78%) 20·1 (10·5) 20·4 (10·4) 3·8 (5·6) 8·2 (6·5)
Other areas 29 19 (66%) 30·0 (13·7) 29·9 (13·2) 8·8 (7·0) 15·4 (5·0)
All areas 173 132 (76%) 21·5 (11·4) 21·7 (11·2) 4·6 (6·1) 9·2 (6·8)
Overall
All areas 883 535 (61%) 20·5 (16·2) 20·7 (16·2) 5·1 (5·4) 7·4 (5·9)
FATA=Federally Administered Tribal Areas. KP=Khyber Pakhtunkhwa.
Table: Characteristics of children with poliomyelitis serotype 1 and matched controls by region 
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received through supplementary immunisation activities 
were either with trivalent, bivalent, or monovalent OPVs, 
but the type of vaccine received was not reported by the 
caregiver. We therefore estimated the number of doses of 
each OPV type received by a child by multiplying the 
total number of OPV doses received through supple-
mentary immunisation activities reported by the care-
giver by the proportion of supplementary immun isation 
activities that used OPVs of each type, as calculated from 
the supplementary immunisation activ ity schedule.18 
Inconsistencies between the reported number of OPV 
doses and the supplementary immun isation activity 
schedule can occur if not all children less than 5 years old 
in a district were immunised during a supplementary 
immunisation activity, if additional OPV doses were 
received outside of the district of residence, or if there is 
caregiver recall error. 
Institutional ethics approval was not sought because 
this is a retrospective study and the databases are 
anonymised and free of personally identiﬁ able 
information.
Statistical analysis 
Summary statistics were reported separately for each 
country and region. Afghanistan and Pakistan were 
divided into seven regions deﬁ ned by the GPEI according to 
patterns of poliovirus epidemiology. Pakistan was separ-
ated into Balochistan province; Khyber Pakhtunkhwa (KP) 
province; the Federally Administered Tribal Areas (FATA); 
a grouping of Punjab province, Gilgit-Baltistan, Azad 
Jammu Kashmir, and Islamabad Capital Territory (grouped 
as Punjab+); and Sindh province. Afghanistan was 
grouped into the southern provinces of Hilmand, 
Kandahar, Nimroz, Uruzgan, and Zabul, and the rest of 
Afghanistan as the remaining region. Incidence rates by 
region were calculated using the population sizes from the 
most recent census data from the Afghanistan Infor-
mation Management Services and the Population Census 
Organisation, Pakistan. A smoothing cubic spline with 
90 degrees of freedom was ﬁ tted to the weekly incidence of 
poliomyelitis and the non-polio acute ﬂ accid paralysis rate.
We used a conditional logistic regression model to 
estimate the odds of paralysis by poliovirus serotypes 1 
and 3 as a function of the number of doses of each 
vaccine received before the onset of paralysis.19 The log 
odds of paralysis was given by: 
where 1–eβm, 1–eβb, and 1–eβt are the per-dose protective 
eﬀ ectiveness of the monovalent (vm), bivalent (vb), and 
trivalent (vt) OPVs against either serotype 1 or 3 and xm, xb, 
Figure 1: Weekly incidence of poliomyelitis associated with serotype 1 or 3 wild-type poliovirus and rate of reporting acute ﬂ accid paralysis associated with other causes
The number of children with poliomyelitis is shown by week of onset of paralysis (coloured dots), with a cubic spline overlaid (coloured line), for serotype 1 in (A) Pakistan and (B) Afghanistan, and for 
serotype 3 in (C) Pakistan and (D) Afghanistan. The grey lines are a cubic spline of the non-polio acute ﬂ accid paralysis rate, given as an annual number of cases per 100 000 children aged less than 
15 years. The arrows at the top of the panels show when SIAs were done, with the length of the arrows proportional to the number of districts included in the campaign and the colours showing the 
vaccine used (trivalent OPV in green, serotype 1 monovalent OPV in red, serotype 3 monovalent OPV in blue, and bivalent OPV in orange). Only SIAs containing the relevant serotype of vaccine are 
shown in each panel. OPV=oral poliovirus vaccine. AFP=acute ﬂ accid paralysis. SIA=supplementary immunisation activity.
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and, xt are the number of monovalent, bivalent, and 
trivalent OPV doses received. The amount of exposure to 
wild virus, ε, for each matched pair is unknown, but was 
eliminated from the analysis by maximising the con-
ditional likelihood.20 Cases of poliomyelitis were matched 
1:1 with randomly chosen control children with non-polio 
acute ﬂ accid paralysis by the methods described pre-
viously (eligible control children were randomly selected 
for each case without replacement, taking the cases in a 
random sequence; appendix). Cases and control children 
were matched by age and the date of onset of paralysis 
(within 3 months) and by district for Pakistan and 
province for Afghanistan (provinces in Afghanistan are 
similar in population size to districts in Pakistan). 
To calculate vaccine-induced population immunity, 
children with non-polio acute ﬂ accid paralysis (control 
children) were assumed to represent a random sample 
of children in the population of the corresponding age. 
The probability of a child being directly protected by 
vaccin ation against serotype 1 poliomyelitis was calcu-
lated from the estimated number of monovalent, 
bivalent, and trivalent OPV doses received and the esti-
mated eﬀ ectiveness of these vaccines as:
Vaccine-induced population immunity among children 
aged 0–2 years was estimated from the average of this 
quantity calculated for each single year age group in the 
acute ﬂ accid paralysis database, weighted to represent 
the underlying age distribution of the population. 
We report vaccine coverage on the basis of the 
proportion of children aged 0–2 years with non-polio 
acute ﬂ accid paralysis who were reported to have received 
more than three doses of OPV. Uncertainty in vaccine 
coverage was accounted for by taking 10 000 bootstrap 
samples (with replacement) from the non-polio acute 
ﬂ accid paralysis cases and recording the percentage of 
children who received four or more doses for each 
sample.21 We report the 2·5th and 97·5th percentiles for 
these bootstrap samples. We used a linear model to 
estimate the slope of temporal trends in annual vaccine 
coverage for each region from 2006 to 2011, and to report 
the strength of the decrease in coverage a p value was 
used, where p<0·05 denotes that at least 95% of 
bootstrapped samples had a decrease in coverage. Linear 
trends in vaccine-induced population immunity against 
serotype 1 were assessed in the same way, but uncertainty 
in vaccine eﬀ ectiveness was also included in bootstrap 
1–(1–νm)xm(1–νb)xb(1–νt)xt
Figure 2: Geographic distribution of children reported with serotype 1 
poliomyelitis in Afghanistan and Pakistan and estimated vaccine-induced 
immunity against this serotype
(A) Population density in districts of Afghanistan and Pakistan. (B) Average 
annual incidence of poliomyelitis caused by serotype 1 wild poliovirus by 
district for 2001–10. (C) Incidence of poliomyelitis caused by serotype 1 
wild poliovirus by district for 2011. FATA=Federally Administered Tribal Areas. 
KP=Kyhber Pakhtunkhwa.
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replicates by randomly sampling from a multivariate 
log-normal distribution with means and variance-
covariance matrix given by the conditional logistic 
regression used to estimate vaccine eﬀ ectiveness. 
Estimated population immunity and annual incidence of 
poliomyelitis were compared for each district-year 
separately. The correlation between population immunity 
and incidence was tested by Spearman’s rank correlation 
coeﬃ  cient. The coverage of routine immun isation was 
assessed on the basis of the proportion of children with 
non-polio acute ﬂ accid paralysis who were reported to 
have received at least three doses of trivalent OPV 
through routine services.
Role of the funding source 
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, decision 
to publish, or preparation of the manuscript. The 
corresponding author had full access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results 
Between Jan 1, 2001, and Dec 31, 2011, there were 883 cases 
of serotype 1 poliomyelitis, 710 in Pakistan and 173 in 
Afghanistan (table). There were 272 cases of serotype 3 
poliomyelitis, 216 in Pakistan and 56 in Afghanistan. 
During 2004–07, case numbers were lower (in Pakistan) 
or remained low (Afghanistan) compared with 2001–03 
despite improved surveillance that resulted in an upward 
trend in the number of reported children with acute 
ﬂ accid paralysis (the non-poliomyelitis AFP rate remained 
above three cases per 100 000 children aged 0–14 years 
from 2004 onwards; ﬁ gure 1). During 2008–11, the number 
of children with serotype 1 poliomyelitis increased in 
Pakistan both in absolute terms and as a proportion of all 
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reported acute ﬂ accid paralysis cases. This increase was 
followed by an increase in Afghanistan in 2011 (ﬁ gure 1). 
The locations of poliomyelitis cases were spatially 
aggregated; the highest numbers of serotype 1 poliomyelitis 
cases were reported in Karachi, Swat, and Khyber districts 
in Pakistan (ﬁ gure 2). In Afghanistan, Maywand and Shah 
Wali Kot districts within Kandahar province had the most 
cases during the study period. In 2011, there were over 
20 cases in Killa Abdullah district in Balochistan and 
between 15 and 20 cases in Quetta and Pishin in 
Balochistan province and Khyber in FATA (ﬁ gure 2). In 
2011, two cases of poliomyelitis caused by serotype 3 were 
identiﬁ ed, both in Khyber district in FATA, Pakistan. 
Of the 883 serotype 1 poliomyelitis cases, 535 (61%) 
were matched with suitable controls (table). The esti mated 
clinical eﬀ ectiveness of a dose of trivalent OPV against 
serotype 1 poliomyelitis was 12·5% (95% CI 5·6–18·8) 
compared with 23·4% (10·4–34·6) for bi va lent OPV 
(likelihood ratio test p=0·067) and 34·5% (16·1–48·9) for 
monovalent OPV (p=0·007). The esti mated eﬀ ectiveness 
of bivalent OPV was non-inferior compared with mono-
valent OPV (p=0·21). There was no evidence of signiﬁ cant 
variation in vaccine eﬀ ectiveness by country or region 
within these countries or by number of vaccine doses 
previously received (likelihood ratio test p=0·22 for the 
per-dose trivalent model; appendix). There were not 
enough cases of serotype 3 poliomyelitis between 2001 
and 2011 to allow accurate estimation of the eﬀ ectiveness 
of each OPV against this serotype. 
The estimated coverage with more than three OPV 
doses among children aged 0–2 years in Afghanistan 
and Pakistan was moderate to high (above 70%). 
However, in Balochistan, FATA, KP, and southern 
Afghanistan there was a signiﬁ cant linear decrease in 
coverage from 2006, to 2011, (ﬁ gure 3; appendix). 
Coverage estimates in Sindh, Punjab+, and the rest of 
Afghanistan remained stable from 2006 to 2011. In 
Balochistan and FATA, there was also a decrease during 
2006–11 in the percentage of children aged 0–2 years 
who received three or more OPV doses through routine 
services (appendix). Routine immunisation coverage 
remained low in southern Afghanistan. 
The percentage of children aged 0–2 years who were 
protected by direct vaccination against poliomyelitis 
varied by location and year (ﬁ gure 3; appendix). Immunity 
to serotype 1 in FATA and Balochistan decreased, despite 
the use of more eﬀ ective vaccines. Coverage estimates for 
Balochistan, KP, and all of Afghanistan further decreased 
in 2011 when compared with 2010, although vaccine-
induced population immunity against serotype 1 either 
increased or remained stable, with the exception of 
southern Afghanistan. 
We noted a signiﬁ cant negative correlation (p<0·0001) 
between the ranked population immunity and annual 
incidence of serotype 1 poliomyelitis in each district 
(Pakistan) or province (Afghanistan; Spearman’s ranked 
correlation coeﬃ  cient –0·11; appendix). 
Discussion
This study provides the ﬁ rst estimates of the clinical 
eﬀ ectiveness and population immunity induced by OPVs 
in Pakistan and Afghanistan, including the eﬀ ectiveness of 
the bivalent vaccine (panel). Our ﬁ ndings support the 
results from India,8 which showed that the immuno-
genicity of two doses of bivalent OPV given to newborn 
babies was non-inferior compared with serotype 1 or 3 
monovalent OPVs. Our results also compare favourably 
with the clinical protective eﬀ ectiveness of the mono valent 
OPV in India (30%, 95% CI 19–41),18 which was valuable in 
improving population immunity and led to the successful 
interruption of wild-type poliovirus trans mission in 2011. 
Consequently, bivalent OPV will be useful in boosting 
population immunity against both circulating serotypes 
during supplementary immun isation activities. Bivalent 
OPV will be used in six of the eight supplementary 
immunisation activities planned for 2012 in Pakistan and 
will be complemented with trivalent vaccine in the 
remaining two supplementary immun isation activities to 
maintain immunity to serotype 2. 
The estimated eﬀ ectiveness of trivalent OPV against 
serotype 1 poliomyelitis in Afghanistan and Pakistan was 
similar to that reported in India.7,19 The poor eﬀ ectiveness 
of OPV in these settings might be partly explained by the 
high prevalence of diarrhoeal disease and enteric infec-
tions including enteroviruses that might interfere with 
seroconversion.4,22 In KP and FATA, the annual average 
incidence of enteroviruses in non-polio acute ﬂ accid 
paralysis stool samples was about 30%, which is similar 
to that reported in Uttar Pradesh and Bihar in India 
(Grassly NC, unpublished). Although this ﬁ nding does 
not implicate enteroviruses speciﬁ cally, it is consis tent 
with the potential role of enteric pathogens in the 
compromised eﬀ ectiveness of OPV.
Since 2006, there has been a decrease in estimated 
vaccination coverage and population immunity against 
poliomyelitis in speciﬁ c regions of Pakistan and 
Afghanistan, which correlated with an increased inci-
dence of cases. In response to this epidemiological 
situation, the President of Pakistan launched a National 
Emergency Action Plan in early 2011.9 Part of this action 
plan included a focus on 33 districts with a high incidence 
of poliomyelitis, largely in KP, FATA, Balochistan, and 
Sindh.10 In late 2011, the National Emergency Action Plan 
was further augmented with tighter oversight and 
vigorous monitoring to improve quality in vaccination 
campaigns.2 However, the analysis presented here 
suggests that vaccination coverage continued to decrease 
in 2011, especially in Balochistan. Additionally, coverage 
continues to be compromised by the ongoing conﬂ ict in 
southern Afghanistan. 
Immunisation is not the only intervention with 
inequitable access in Pakistan and Afghanistan, but poor 
access to it contributes with other social determinants to 
poor child health in these areas.23 Armed conﬂ ict and 
concerns about security are major challenges that can 
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limit access to children during vaccination campaigns, 
in addition to disrupting routine health and immun-
isation services.24 For example, we noted that access to 
routine immunisation decreased in Balochistan and 
FATA in Pakistan, with just 25–33% of children under 
3 years old reported to have received three or more doses 
of OPV through routine services in 2011 (appendix). 
This ﬁ nding contrasts with improvements in routine 
immunisation coverage in areas free from conﬂ ict such 
as northern Afghanistan. However, weak service delivery 
has also resulted from poor management and scarcity of 
local accountability;10,25 even so, polio has been success-
fully eliminated during times of conﬂ ict in many 
other countries.24
The precision of our estimates of vaccine eﬀ ectiveness 
might be limited by the accuracy of the caregiver’s 
report of the number of doses of OPV received by a 
child and diﬃ  culties in correctly inferring the type of 
vaccine received during supplementary immunisation 
activities. Although vaccination cards were used when 
recording the number of doses of trivalent OPV received 
through routine immunisation services, these cards 
were only available for 25% of children and the number 
of vaccine doses received through supplementary 
immunisation activities was not recorded. Errors in the 
reported numbers of vaccine doses among cases and 
controls could lead to an underestimate of vaccine 
eﬀ ectiveness. Additionally, the inability of the statistical 
method of matching by location, time, and age to control 
for diﬀ erences in exposure to wild-type polioviruses 
might further con tribute to underestimation of vaccine 
eﬀ ectiveness.
We attempted to assess the extent of caregiver recall 
error in several ways, including by examining the 
correlation between caregiver reports of supplementary 
immunisation activity doses and administrative records of 
supplementary immunisation activities, the odds of 
poliomyelitis as a function of the reported number of 
doses of vaccine received, and the association between the 
estimated vaccine-induced population immunity on the 
basis of caregiver reports of vaccination history and the 
incidence of poliomyelitis. In each case, results based on 
caregiver recall were consistent with those expected based 
on the other data sources, although comparison with the 
supplementary immunisation activity schedule suggested 
that at higher dose numbers there was a preference for 
reporting seven, ten, 12, 15, and 20 doses (appendix). 
These ﬁ ndings are in agreement with a study in India,7 
where information from detailed interviews with parents 
of children with poliomyelitis showed some small errors 
in recall of the number of vaccine doses received by their 
children but no consistent upwards or downwards bias. 
Furthermore, vaccination history is taken at a time when 
both the caregiver and interviewer are unaware of the 
polio status of the child, thus removing the possibility of 
diﬀ erential reporting from cases and controls. The 
ﬁ ndings of a greater eﬀ ectiveness of monovalent OPVs 
and weak evidence of greater eﬀ ectiveness of bivalent 
vaccine than trivalent OPV are therefore likely to be robust 
to recall error of caregivers. We also focused on children 
aged 0–2 years when estimating vaccination coverage and 
population immun ity to avoid recall errors that might 
have been more frequent among older children. Children 
in this age group were also chosen because they are more 
repre sentative of the at-risk population. 
The negative correlation of population immunity with 
incidence shows protective immunity within the popu-
lation. However, in some districts there was not the 
expected reduction in cases despite high estimated 
population immunity. A limitation of this analysis is that 
non-polio acute ﬂ accid paralysis cases are assumed to be 
representative of the entire population. In reality, even 
within districts there are probably areas not reached by 
surveillance and vaccination teams, resulting in hetero-
geneities in population immunity that are not captured 
in the analysis. 
In the past 10 years there have been many developments 
in the control of poliomyelitis that should enable elim-
ination in Afghanistan and Pakistan. However, an 
increase in incidence has occurred despite the 
introduction of more eﬃ  cacious vaccines because of 
steep decreases in vaccination coverage. In 2011, 40% of 
children under 3 years old in Balochistan and FATA in 
Pakistan and in southern Afghanistan were estimated to 
be unprotected against serotype 1, the predominant 
circulating wild polio virus. If vaccination coverage 
during the two trivalent and four bivalent OPV campaigns 
planned in Afghanistan and Pakistan in 2012 could be 
Panel: Research in context
Systematic review
We searched PubMed and Web of Science with the search terms “poliomyelitis AND 
(Pakistan OR Afghanistan)” and “bivalent AND poliovirus”, with no date limits set, on 
March 7, 2012. For over 10 years the incidence and epidemiological status of poliomyelitis 
in both countries have been reported annually in the Weekly Epidemiological Record.15 
Monitoring of vaccine coverage during mass campaigns has been limited, but ﬁ ndings 
from a lot-quality assurance sampling study in Pakistan suggested that coverage during 
mass campaigns in 2009 was low.13 The only immunogenicity study of the present 
formulation of bivalent OPV that we identiﬁ ed was done in India in 2008, in which the 
vaccine was non-inferior compared with monovalent vaccines for serotypes 1 and 3.8 The 
eﬀ ectiveness of this bivalent OPV has not been reported previously.
Interpretation
We found the eﬀ ectiveness of serotypes 1 and 3 bivalent OPV against poliomyelitis 
caused by serotype 1 wild poliovirus to be non-inferior compared with monovalent OPV. 
However, despite the use of these more eﬀ ective vaccines during recent vaccination 
campaigns, estimated population immunity among children in key regions of 
Afghanistan and Pakistan decreased between 2006 and 2011 as a result of substantial 
drops in vaccination coverage. This decrease in population immunity resulted in an 
increased incidence of serotype 1 poliomyelitis during 2010–11. Vaccination coverage 
must be considerably improved in 2012 through higher quality campaigns and routine 
programmes if global eradication of poliomyelitis is to be achieved.
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increased to at least 80%, and if persistently missed 
children could be reached by the programme, the 
proportion of unprotected children would decrease to 
less than 10% and eradication would become feasible. To 
achieve this ambitious goal, major improvements in 
vaccination delivery will be needed in the face of armed 
conﬂ ict and concerns about security.
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